Drugs / HYZETIMIBE
HYZETIMIBE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT03433196 | Jun 2016 → Jun 2018 | hyperlipoproteinemia | Zhejiang Hisun Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03464682 | Feb 2015 → Dec 2018 | hyperlipoproteinemia | Zhejiang Hisun Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT02087917 Comparator | Mar → Sep 2014 | hyperlipoproteinemia | Zhejiang Hisun Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03413462 Comparator | Apr 2016 → Apr 2018 | hyperlipoproteinemia | Zhejiang Hisun Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| — | NCT06096909 Comparator | Nov 2023 → Nov 2025 overdue | acute coronary syndrome | China National Center for Cardiovascular Diseases | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HYZETIMIBE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297389 ↗ |
| Known as | HS-25 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03433196 ↗ |
| Known as | Hybutimibe | “Cholesterol absorption inhibitors (like Ezetimibe and Hybutimibe) are based on physician decisions” NCT06096909 ↗ |
| Modality | Small molecule | — CHEMBL4297389 ↗ |
| Route | Oral | “is to be administered orally once daily in the morning with or without food” NCT02087917 ↗ |